EP. 1: Collaborative approaches to treating advanced prostate cancer
The role of urologists in working with medical oncologists to treat patients with advanced prostate cancer, with special considerations for early referral.
EP. 2: AR-targeted therapies for advanced prostate cancer
Julie N. Graff, MD, of OHSU Knight Cancer Institute, comments on the impact of the availability of newer-generation androgen receptor inhibitors on treatment outcomes for patients with advanced prostate cancer.
EP. 3: AR-targeted therapies for mCSPC
Various factors that medical oncologists consider when selecting to treat metastatic castration-sensitive prostate cancer with either apalutamide or enzalutamide.
EP. 4: AR-targeted therapies for nmCRPC
Julie N. Graff, MD, highlights the efficacy associated with the use of androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer.
EP. 5: AR inhibitor treatment selection in nmCRPC
Considerations that factor into which androgen receptor inhibitor is selected as treatment for nonmetastatic castration-resistant prostate cancer.
EP. 6: Next steps investigating AR inhibitors in advanced prostate cancer
Based on long-term data and clinical experience treating advanced prostate cancer with androgen receptor inhibitors, Drs Julie N. Graff and Benjamin H. Lowentritt suggest ideas for future study.
EP. 7: PSA kinetics in advanced prostate cancer
In response to a presentation from AUA 2021, Dr. Julie N. Graff considers the role of PSA kinetics as prognostic markers in advanced prostate cancer.
EP. 8: Interpreting real-world data in advanced prostate cancer
Current limitations of real-world data available that support the use of novel therapies, including androgen receptor inhibitors, as treatment for advanced prostate cancer.
EP. 9: Novel dual agents for advanced prostate cancer
A recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
2 Clarke Drive Cranbury, NJ 08512